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Abstract: Cannabidiol (CBD)-based oil preparations are becoming extremely popular, as CBD
has been shown to have beneficial effects on human health. CBD-based oil preparations are
not unambiguously regulated under the European legislation, as CBD is not considered as
a controlled substance. This means that companies can produce and distribute CBD products derived
from non-psychoactive hemp varieties, providing an easy access to this extremely advantageous
cannabinoid. This leaves consumers with no legal quality guarantees. The objective of this
project was to assess the quality of 14 CBD oils commercially available in European countries.
An in-depth chemical profiling of cannabinoids, terpenes and oxidation products was conducted
by means of GC-MS and HPLC-Q-Exactive-Orbitrap-MS in order to improve knowledge regarding
the characteristics of CBD oils. Nine out of the 14 samples studied had concentrations that differed
notably from the declared amount, while the remaining five preserved CBD within optimal limits.
Our results highlighted a wide variability in cannabinoids profile that justifies the need for strict
and standardized regulations. In addition, the terpenes fingerprint may serve as an indicator of the
quality of hemp varieties, while the lipid oxidation products profile could contribute in evaluation of
the stability of the oil used as milieu for CBD rich extracts.
Keywords: cannabidiol; CBD oil; terpenes; hemp seed oil; GC-MS; HPLC-Q-Exactive-Orbitrap-MS
1. Introduction
Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the most common cannabinoids in
medical cannabis preparations [1]. The are both responsible for a variety of pharmacological actions
that can have remarkable applications, but unlike THC, CBD does not possess any psychoactive
effects [1]. Several studies suggest that CBD can be effective in treating epilepsy and other
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neuropsychiatric disorders, including anxiety and schizophrenia [2–4]. CBD may also be effective
in treating post-traumatic stress disorder and may have anxiolytic, antipsychotic, antiemetic and
anti-inflammatory properties [5–7]. This plethora of pharmacological activities has led to rapid
changes in the cultural, social and political legal viewpoints regarding the utilization of cannabis-based
preparations [8]. Although there is still a complicated legal milieu that calls for caution, it is undeniable
that there is an enormous interest from consumers/patients in the utilization of CBD dietary
supplements. This has created an exploding industry of CBD products in Europe and around the
world. “CBD enriched oils”, obtained from extraction of different Cannabis sativa L. chemotypes with
high content of CBD, are the most popular products used [9–12].
Since CBD, in contrast to THC, is not a controlled substance in the European Union [13]
several companies produce and distribute CBD-based products obtained from inflorescences of
industrial hemp varieties. However, due to the lack of specific regulations, no analytical controls are
mandatory for CBD-based products, leaving consumers with no legal protection or guarantees about
the composition and quality of the product they are acquiring. Currently, CBD-based products are
not subject to any obligatory testing or basic regulatory framework to determine the indication area,
daily dosage, route of administration, maximum recommended daily dose, packaging, shelf life and
stability. Exceptions are galenical “CBD oil” prepared by pharmacists following medical prescriptions
in several European Union countries such as Germany, Italy and Holland. The German Drug Codex
(DAC), which is published by the Federal Union of German Associations of Pharmacists (ABDA)
and functions as a supplementary book to the Pharmacopoeia, suggests a preparation of 5% CBD in
medium chain triglycerides oil also indicating detailed analytical controls of galenic preparations [14].
In Italy medical cannabis represents a multifaceted reality [9–12]. At present Dutch Bedrocan
varieties (Bedrocan, Bediol, Bedica and Bedrolite as representative) [15] and the new strain FM2
produced by Military Pharmaceutical Chemical Works of Florence, Italy (authorized in November
2015 by a Ministerial Decree) can be prescribed to treat a wide range of pathological conditions [16].
Indeed. Italian galenic pharmacies are authorized to prepare precise cannabis doses for vaping, herbal
teas, resins, micronized capsules and oils. The oil preparation has received considerable attention
since it is easy to adjust the individual administration dose required throughout the treatment period,
and due to the enhanced bioavailability of its active compounds [9–12]. Among abovementioned
strains, Bedrolite with CBD and THC contents of 9% and <1%, respectively, is frequently used for
the preparation of galenic “CBD-based oil”. Anyway, pharmacies are also allowed to distribute CBD
oils obtained from hemp, but declared as additives or aromatic preparations, if produced in Italy or
designed as dietary supplement if imported from other European countries.
Cannabis sativa L. has been cultivated throughout the world for industrial and medical purposes.
The European Union permits the cultivation of plants for hemp products based on the THC content
being less than 0.2%. EU Regulation 1307/2013 [17] states that hemp farmers are required to use seeds
of cannabis varieties included in the European Union catalogue. In general, specialized extraction
procedures, among which the most common is supercritical CO2 extraction, are used to draw out
an extract rich in CBD from the cannabis to obtain CBD oil formulations [18,19]. This product also
contains other biological active compounds such as omega-3 fatty acids, vitamins, terpenes, flavonoids
and other phytocannabinoids like cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN)
and cannabidivarian (CBCV) [10–12].
Among non-cannabinoids compounds, special attention must be paid to terpenes that
represent the largest group (more than 100 different molecules) of cannabis phytochemicals [20–23].
Monoterpenes, diterpenes, triterpenes and sesquiterpenes are important components present in
the cannabis resin responsible for its unique aromatic properties. Due to their ability to easily
cross cell membranes and the blood-brain barrier, they can also influence the medicinal quality
of different cannabis chemotypes [24]. Several therapeutic approaches based on the combined use
of cannabinoids and terpenes have been developed recently. Particularly, treatment of sleeping
disorders and social anxiety by adding caryophyllene, linalool and myrcene to CBD/THC extracts
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gave encouraging results [25]. In addition, differences between the pharmaceutical properties of diverse
Cannabis sativa L. varieties have been attributed to strict interactions, defined as ‘entourage effects’,
between cannabinoids and terpenes as a result of synergic action [25]. Recently Pagano et al. [26]
investigated the different effect of a pure CBD preparation versus a standardized Cannabis sativa
extract with the same concentration of cannabidiol (CBD) in the remission of mucosal inflammation in
a mouse models of colitis. The author reveled that under the same experimental conditions, pure CBD
just partially ameliorated colitis, while Cannabis sativa L. extract almost entirely reduced the injuries.
These findings sustain the rationale of the ‘entourage effect’ achievable by combining CBD with other
minor Cannabis constituents.
The quality of Cannabis macerated oils has already been investigated in previous research
demonstrating the importance of selecting correct preparation methods and conditions as well as
studying the evolution of major and minor compounds (cannabinoid and terpenes) during storage in
order to define the ideal shelf-life and management guidelines (storage temperature) [12]. Oxidation
products derived from fatty acid degradation during the storage period of macerated oils are critical for
overall formulation stability [27,28]. Galenic preparations are usually prepared by using pharmacopeia
grade olive oil (FU) to minimise the formation of large quantities of aldehydes and ketones that can
also influence the digestibility of the macerated oil [9,12,29].
Since the production of CBD-based oils as dietary supplements has increased rapidly, and since
they are frequently used for therapeutic purposes, the main scope of this study was to assess the overall
quality of 14 CBD oil preparations produced in different European countries and purchased on the
Internet and highlight possible criticisms. Moreover, a Bedrolite macerated oil prepared as a galenic
product was used as a reference therapeutic formulation. In order to define and increase knowledge
about the characteristic of CBD oils, an in-depth chemical profiling of cannabinoids, terpenes and
oxidation compounds by means of GC-MS and HPLC-Q-Exactive-Orbitrap-MS analytical platforms
was presented herein.
2. Results and Discussion
2.1. Cannabinoids Content
Current ambiguous all-purpose regulations allow huge variations in the quality and safety of the
CBD-based preparations available on the market and clear labelling regarding the exact concentration
of CBD is not yet mandatory. Our results demonstrate that CBD concentrations were not always in
accordance with producer information (Table 1). As a matter of fact, nine out of 14 tested samples
presented concentrations that differed notably from the declared amount, while the remaining five
preserved CBD levels within optimal limits (the variation was less than 10%). Our analysis also
revealed that two preparations (particularly oils 8 and 10) exhibited higher levels of CBD than those
specified by producers, while in another two (samples Oil_3 and Oil_14) the CBD content was far
inferior to the stated values. In one sample, the theoretical CBD concentration was not indicated on the
label and therefore values obtained could not be compared to the producer’s statement. Taken together,
the results highlighted the extreme variability of the commercialised CBD oil preparations, justifying
the need for stricter regulations/controls. Precise information regarding the composition of each
lot that is available on the market is crucial for consumers who have to be able to properly adapt
the recommended dose to the available/purchased preparation [9]. These results are in agreement
with those obtained from a preliminary study toward the labeling accuracy of cannabidiol extracts
preparations from products available on the US market. In the tested products, 26% contained less
CBD than labeled, which could negate any potential clinical response [30]. The over labeling of CBD
products in the study was similar in magnitude to levels that triggered warning letters to 14 businesses
in 2015–2016 from the US Food and Drug Administration suggesting that there is a continued need for
federal and state regulatory agencies to take steps to ensure label accuracy of these consumer products.
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Although CBD is a principal constituent of the examined cannabis oil extracts, the original plant
is only capable of producing its acid form, cannabidiolic acid (CBDA). Decarboxylation of CBDA
catalysed by thermal exposure during extraction conditions leads to the conversion of CBDA to the
CBD as the corresponding decarboxylated (neutral) counterpart. Therefore, the determination of CBDA
is important in order to evaluate the CBDA decarboxylation rate and effectiveness of the reaction
during the extraction process [31]. Interestingly, looking through the web sites of the CBD oil producers
enrolled in this survey, it can be found that some of them published an analytical report in which only
the total CBD content as the sum of CBD + (0.877 CBDA) is reported. This is quite problematic as the
biological effects of the neutral and acidic forms are remarkably different [5]. Generally, expressing
the CBD content as a sum of the acidic and neutral forms is conditioned by the analytical method
applied. Concretely, it occurs when gas chromatography (GC), one of the most commonly used
analytical platforms for cannabinoid analysis, is used [31]. It involves the heating of the sample at
high temperature in the injector prior to the chromatographic separation that leads inevitably to the
decarboxylation of the cannabinoid acids. Therefore, the analytical result is the sum of the acid and
neutral forms. The GC method is still officially employed by the authorities for the determination of
cannabinoids, but obviously is unsuitable. A few research groups continue to suggest that an accurate
cannabinoid profile should be evaluated by determining the acid and neutral forms separately [12,31].
Results obtain in this study confirms this necessity. Employing the LC-HRMS technology, we were
able to distinguish the acidic form from neutral CBD, and to examine the wide concentration range.
As can be seen in Table 1, in the majority of the samples the CBDA concentration was found to be
negligible compared to the amount of CBD (for example, samples Oil_4 and Oil_15). On the contrary,
there were a few samples with a significant amount of CBDA. A striking example is Oil_3, in which the
CBDA content exceeded CBD, and only the sum of both forms justified the CBD percentage declared
by the producer. Furthermore, it is evident that the label concentration of CBD in Oil_12 is reached
only when the sum of both forms is considered, bearing in mind the significant amount of CBDA.
Nevertheless, all producers underline that their manufacturing methods yield the so called full
spectrum extract, which means that hemp extracts contain different phyto-cannabinoids, including
THC, CBN, CBG, THCA, CBGA and others, depending from cannabis strain and extraction method.
In order to achieve full-spectrum in a hemp extract, the profile of bioactive compounds that a plant
flower contains must be transferred into the extract itself without compromising any aspect of
the profile.
In comparison with previous works available on cannabis oil [9–11,31] we employed a HRMS
method that provided more complete information regarding the cannabinoids profile and amount in
the oil composition. Actually, besides CBD as a principal cannabinoid, we were able to detect and to
quantify the six most significant cannabinoids, including the essential ones (THC, THCA and CBDA)
along with quantification of CBN, CBG and CBGA. The obtained results clearly show that 12 out of
14 samples contained THC which is attention-grabbing because of its potential intoxicating activity.
The THC content showed the considerable variability in the analysed samples, but was mainly at
the levels describable as low (0.2%) [17]. Only one among all THC-positive sample (Oil_6) contained
a considerable amount of THC (0.35%), which is matter of concern because the manufacturer declared
the product to be THC-free. This result highlights the importance of also specifying the amount of
THC or any another intoxicating cannabinoid present in commercialised CBD oils.
CBN was quantifiable in the vast majority of samples (except Oil_14). Its detection is of great
importance as it is not considered to be a natural cannabinoid but rather an artefact formed by THC
oxidation during plant aging, by use of an inadequate extraction procedure or inappropriate storage
conditions [32]. Therefore, its determination may assist in the evaluation of the quality of CBD oils
with regards to the raw plant material used, extraction method applied and storage. For example,
in the sample Oil_13 the quantity of the CBN was more than twice the amount of THC. Considering
CBN as a degradation product of THC, it would be better to think through the sum of THC+CBN as
a relevant parameter for the evaluation of initial THC concentration in the oil extract. In addition,
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CBN, though much less psychoactive than THC, express sedative effects [33,34] which is why its
content should be indicated on the label along with THC. It is well known that THC derives from the
decarboxylation of tetrahydrocannabinolic acid (THCA) [20], and this is the reason why the amount of
THCA was quantified in this study. Our results did not reveal any significant presence of either THCA
(Table 1) or cannabigerolic acid (CBGA) which is the precursor of the all other cannabinoid acids.
CBGA gives by decarboxylation cannabigerol (CBG) that either was completely absent or present
in minor quantities. The quantification of CBGA and CBG did not turn out to be imperative, but
their presence could serve as a confirmation that the oil sample contains a natural, full spectrum
cannabis extract. Furthermore, employing the retrospective analysis, several other minor “untargeted”
compounds were detected by means of the Orbitrap (Thermo Fisher Scientific, San Jose, CA, USA)
® analyser. Among others (data not shown) it is important to highlight the persistent occurrence of
CBDV in all analysed samples. Figure 1 shows the fragmentation pattern of CBDV and CBD. Bearing
in mind that this compound has expressed significant physiological activity [33] and that accompanies
the CBD as its analogue, it should be included in any quality evaluation of full spectrum CBD oil
preparations. Besides, we noticed that when the hemp seed oil was used as matrix, the signal of CBDV
augments notably, which means that maybe one portion of CBDV derives from hemp oil, not from
flower extract [34].
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Figure 1. Retrospective data analysis reveals the occurrence of CBDV: full MS-dd-MS2 chromatogram
and relative fragmentation pattern of parent ion (287.20048) obtained in dd-MS2 acquisition mode.
For the comparison, the CBD signal and fragmentation pattern is also presented.
Bedrolite oil extract (Oil_1) obtained by a recently published procedure [12], is a defined galenic
formulation that has been used for distinct therapeutic purposes. It was included in this study
as a “reference material” from a well-defined starting material (cannabis plant variety) and made
using a standardized/authorized preparation procedure. There are at least two reasons to use the
cannabinoid profile of Bedrolite oil extract as a reference point in the evaluation of CBD-rich hemp oils.
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Firstly, it can be considered as a full-spectrum extract that preserves the natural ratios of cannabinoids,
any impurities that can compromise the experiments should be absent. Secondly, many consumers
tend to replace galenic oil preparations (such Bedrolite oil extract) with CBD-rich hemp oil extract,
due to the fact that a medical prescription is required for the former. Our study revealed that Bedrolite
oil extract contains 0.8% of CBD. This is in agreement with theoretical percentage (0.9%) that should be
found in the Bedrolite oil extract: the inflorescence contains 9% of CBD and the dilution ratio during
the extraction is 1:10. However, as regards the cannabinoids profile (Table 1), it is evident that the
quantities of CBDA, THC, THCA and CBGA are inferior compared with CBD-rich hemp oil extracts.
These data are of great importance as they highlight the reduced concentration of all cannabinoids in
Bedrolite oil extract compared to CBD hemp oil extract.
The reasons for all the abovementioned variations between examined samples are numerous and
multiple. The final composition of CBD-rich hemp oil extracts depends on the chemotype and quality
of the industrial hemp used, but it is also conditioned by the extraction method applied. Unfortunately,
not all producers indicate the extraction method used. Only four declared the use of supercritical CO2
fluid extraction, which is shown to be the method of choice in that the low temperature and inert
atmosphere results in higher CBD yields [18,19]. However, the main drawback of this technology is
its high cost, and it is reasonable to assume that solvent extraction is also used for the inexpensive
industrial processing. However, it is questionable if this is a correct choice for a product for human
consumption because residual solvents (typically hexane, ethanol, isopropyl alcohol, toluene, benzene,
xylene and acetone) may contaminate the final product [32]. Without having complete information
on the methods of CBD oils preparation, we investigated the occurrence of the most frequently used
extraction solvents as solvent residues. Our analysis revealed the sporadic incidence of acetone
(Table 2, ketones section) that is more probably present as a lipid oxidation product rather than
as a true residual solvent. Nevertheless, the presence of some volatile compounds that might be
considered as problematic impurities from solvents residues was detected (Table 2, miscellaneous
section). Namely, the samples Oil_4 and Oil_6 showed the presence of 1,3-dimethylbenzene while in
the sample Oil_3, 1,2,4-trimethylbenzene was detected. Those aromatic compounds were not present
in galenic preparation (Oil_1).
2.2. Volatile Fingerprint: Terpene Profile and Secondary Lipid’s Oxidation Products
Terpenes and cannabinoids share biosynthetic pathways and, in fact, cannabinoids are
terpenophenolic compounds. In Cannabis plants, terpenes are secreted and stored together with
cannabinoids in glandular trichomes. Considering this fact also in relation to recent evidence of the
synergic action of terpenes and cannabinoids (“entourage effect”), a comprehensive survey of terpenes
is fundamental for the evaluation of cannabis oil preparations as dietary supplement with therapeutic
applications. Complete data concerning the terpenes profile are summarized and reported in Table 2.
Overall, up to 110 volatile compounds composed the volatile fingerprint, including 48 terpenes that
are further divided into classes as presented in Figure 2. The sample Oil_6 contained an extremely
high amount of terpenes compared with all other samples. ↵-Pinene,  -myrcene and limonene are the
most concentrated terpenes in this preparation, which points toward the extremely efficient extraction
method applied. Samples 5, 12 and 14 contained a distinct number of various terpenes, although in
far lower concentration compared to sample Oil_6. Apparently, these formulations were obtained by
an extraction process able to preserve naturally occurring terpenes profile from initial Cannabis sativa
plants, as their terpene profile is in accordance with those already published in literature [12,21–24,35].
Similarly, Bedrolite oil extract (Oil_1) contains various terpene structures, reflecting the initial plant
profiling. A particular profile is observed for the sample Oil_4 that showed a different terpene
fingerprint compared to the other oils as it predominantly contains monoterpene subclass molecules.
It has previously been demonstrated how the preparation method used for the production of cannabis
extracts is able to affect the presence of different terpenes [18,19], and this is most probably reason of
such a specific terpene profile found in Oil_4.
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-
n.d.
-
n.d.
-
0.77
0.11
n.d.
-
1.10
-
n.d.
-
969
23.07
1-O
cten-3-ol
n.d.
-
3.90
0.47
n.d.
-
n.d.
-
0.73
0.15
1.73
0.03
1.09
0.51
n.d.
-
960
23.17
1-H
eptanol
n.d.
-
0.83
0.13
n.d.
-
n.d.
-
0.50
0.01
2.49
0.10
n.d.
-
n.d.
-
1059
25.48
1-O
ctanol
n.d.
-
n.d.
-
1.29
0.11
n.d.
-
0.59
0.03
5.23
0.63
n.d.
-
n.d.
-
1068
27.98
3,3,6-Trim
ethyl-1,5-heptadien-4-ol
2.39
0.46
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1036
31.59
↵
-Toluenol
0.42
0.03
2.74
0.59
n.d.
-
n.d.
-
2.36
0.16
3.96
0.47
3.22
0.23
n.d.
-
1136
32.06
Benzeneethanol
0.51
0.04
1.39
0.32
n.d.
-
n.d.
-
2.73
0.16
5.05
0.58
3.43
0.22
0.76
0.01
Total
6.06
14.68
1.29
0.55
11.70
28.01
13.18
12.28
A
ldehydes
508
2.31
Propanal
n.d.
-
n.d.
-
0.77
0.03
n.d.
-
0.96
0.04
1.10
0.08
0.97
0.05
n.d.
-
574
3.23
2-M
ethyl-2-propenal
n.d.
-
n.d.
-
0.61
0.03
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
643
3.74
2-M
ethyl-butanal
1.73
0.02
0.56
0.02
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
643
3.83
3-M
ethyl-butanal
0.90
0.16
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
785
10.12
H
exanal
0.70
0.02
5.57
0.14
10.15
0.29
n.d.
-
2.97
0.17
6.89
0.01
2.60
0.15
3.42
0.03
905
15.05
H
eptanal
0.76
0.03
n.d.
-
1.03
0.03
n.d.
-
n.d.
-
n.d.
-
0.67
0.10
0.62
0.03
814
16.24
2-H
exenal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.19
0.12
n.d.
-
1.41
0.03
n.d.
-
1005
18.74
O
ctanal
n.d.
-
n.d.
-
2.47
0.02
n.d.
-
2.03
0.23
17.40
0.16
1.87
0.03
n.d.
-
913
19.72
2-H
eptenal
n.d.
-
3.10
0.05
2.61
0.22
n.d.
-
1.86
0.09
6.44
0.41
1.59
0.03
1.22
0.05
1104
21.67
N
onanal
0.73
0.16
n.d.
-
2.63
0.30
n.d.
-
n.d.
-
4.92
0.03
1.07
-
n.d.
-
1013
22.53
2-O
ctenal
n.d.
-
n.d.
-
0.68
0.05
n.d.
-
n.d.
-
2.07
0.08
n.d.
-
0.61
0.02
921
24.01
2,4-H
eptadienal
n.d.
-
1.27
0.05
0.74
0.14
n.d.
-
n.d.
-
7.97
0.34
n.d.
-
n.d.
-
982
24.77
Benzaldehyde
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.86
0.01
25.84
0.45
n.d.
-
n.d.
-
1174
28.04
3,7-D
im
ethyl-2,6-octadienal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
44.49
4.40
n.d.
-
n.d.
-
Total
4.82
10.50
21.68
n.d.
10.87
117.14
10.19
5.88
Esters
487
2.63
A
cetic
acid-m
ethylester
0.78
0.02
0.72
0.04
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
586
3.33
A
cetic
acid-ethylester
n.d.
-
8.70
0.12
302.74
12.32
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
686
5.35
A
cetic
acid-propylester
n.d.
-
n.d.
-
1.45
0.07
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
721
6.77
A
cetic
acid-2-m
ethyl-propylester
n.d.
-
n.d.
-
5.39
0.06
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
785
9.76
A
cetic
acid-buthylester
n.d.
-
n.d.
-
1.17
0.11
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
820
12.27
1-Butanol-3-m
ethylacetate
n.d.
-
n.d.
-
7.46
0.17
n.d.
-
n.d.
-
16.98
0.21
n.d.
-
n.d.
-
992
19.62
3-H
exen-1-ol-acetate
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
0.64
0.02
n.d.
-
1183
22.24
Butanoic
acid-hexylester
n.d.
-
n.d.
-
n.d.
-
0.60
0.02
n.d.
-
n.d.
-
n.d.
-
n.d.
-
Total
0.78
9.42
318.21
0.60
n.d.
16.98
0.64
n.d.
M
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Table
2.C
ont.
O
ilSam
ples
1
2
3
4
5
6
7
8
M
atrix
FU
O
il
H
em
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Seed
O
il
O
live
O
il
M
C
T
O
il
O
live
O
il
H
em
p
Seed
O
il
O
live
O
il
H
em
p
Seed
O
il
R
I
a
R
.T
b
C
om
pound
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
lcohols
K
etones
455
2.50
2-Propanone
1.76
0.13
3.50
0.47
8.56
0.57
n.d.
-
2.46
0.51
5.03
0.65
1.78
0.14
0.96
0.01
1161
13.19
1-(1,3-dim
ethyl-3-cyclohexen-1-yl)-Ethanone
n.d.
-
1.89
0.18
n.d.
-
n.d.
-
n.d.
-
2.07
0.15
n.d.
-
0.90
0.06
853
14.89
2-H
eptanone
n.d.
-
3.32
0.09
0.71
0.02
n.d.
-
2.69
0.16
n.d.
-
2.74
0.06
1.00
0.06
952
18.57
2-O
ctanone
n.d.
-
4.63
0.64
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
960
19.99
6-O
cten-2-one
n.d.
-
0.86
0.11
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
987
20.17
6-M
ethyl-5
hepten-2
one
1.25
0.04
8.97
1.20
10.55
0.42
n.d.
-
2.28
0.11
17.04
0.14
1.63
0.00
2.26
0.13
960
21.96
3-O
cten-2-one
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
962
22.51
K
etone
0.69
0.02
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
968
24.67
3,5-O
ctadien-2-one
n.d.
-
n.d.
-
4.94
0.41
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
Total
3.70
23.17
24.77
n.d.
7.44
24.14
6.15
5.12
Terpenes
939
6.67
↵
-Pinene
14.25
0.55
21.47
0.38
n.d.
-
73.23
9.63
112.95
1.47
5883.13
22.05
119.09
0.23
52.84
1.11
932
7.03
↵
-Thujene
0.98
0.17
1.18
0.08
n.d.
-
0.79
0.08
2.86
0.19
44.54
1.08
3.24
0.10
n.d.
-
961
8.67
C
am
phene
n.d.
-
n.d.
-
n.d.
-
0.94
0.27
1.57
0.09
65.97
3.91
1.60
0.01
0.95
0.03
989
10.75
 
-Pinene
4.15
0.05
4.45
0.08
n.d.
-
23.36
4.71
35.65
2.06
625.28
4.35
37.08
0.48
17.91
0.28
985
11.66
Sabinene
n.d.
-
1.26
0.07
n.d.
-
n.d.
-
1.66
0.01
98.17
0.06
1.53
0.08
n.d.
-
879
11.74
2,4(10)-Thujadien
n.d.
-
0.85
0.00
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1017
12.99
 -3-C
arene
1.73
0.03
0.61
0.09
n.d.
-
7.42
1.33
50.22
1.18
4.69
0.31
51.31
2.68
6.17
0.50
1015
13.81
↵
-Phellandrene
3.70
0.14
3.90
0.09
n.d.
-
2.91
0.65
6.78
0.01
4.97
0.04
8.06
0.18
1.85
0.09
991
14.24
 
-M
yrcene
108.13
0.09
34.63
1.00
9.14
0.48
419.53
33.32
389.37
20.60
2908.00
60.01
419.01
6.04
189.05
1.74
1026
14.44
↵
-Terpinene
3.60
0.38
10.01
0.56
n.d.
-
2.44
0.07
5.51
0.17
34.87
3.09
6.82
0.12
1.74
0.01
1038
15.31
Lim
onene
6.05
0.01
8.03
0.44
1.60
0.07
65.17
7.36
23.67
1.33
8841.42
171.34
20.17
0.26
23.97
0.34
1045
15.49
Eucalyptol
3.67
0.01
5.60
0.35
7.15
0.26
2.65
0.13
4.18
0.27
13.66
1.60
3.09
0.07
8.62
0.12
946
15.61
 
-Phellandrene
7.16
0.14
4.80
0.52
n.d.
-
8.40
0.80
19.02
1.05
61.90
4.71
20.05
0.16
7.38
0.22
976
17.05
C
is-ocim
ene
0.48
0.02
2.17
0.17
0.48
0.00
16.55
1.07
21.17
0.88
7.13
0.24
19.24
0.23
5.50
0.11
1066
17.15
 -Terpinene
5.38
0.01
5.84
0.58
0.59
0.06
2.11
0.09
4.80
0.23
499.58
9.26
4.61
0.08
2.48
0.04
1000
17.24
Terpene
n.d.
-
n.d.
-
2.48
0.24
n.d.
-
2.59
0.02
17.49
0.05
1.82
0.04
n.d.
-
1029
17.60
 
-O
cim
ene
21.75
1.08
7.55
0.53
9.96
0.48
194.00
21.13
192.39
5.19
22.82
0.17
213.15
1.26
42.00
1.72
1034
18.01
p-C
ym
ene
3.13
0.11
8.53
0.97
0.81
0.01
2.98
0.33
12.37
0.05
144.55
1.92
10.02
0.15
5.62
0.09
1094
18.43
↵
-Terpinolene
62.12
0.67
7.48
0.80
n.d.
-
111.31
14.58
265.95
16.97
33.73
0.11
297.20
3.11
73.16
3.13
1177
22.74
Para-cym
enyl
13.97
0.88
11.28
0.16
n.d.
-
3.30
0.82
64.48
5.97
134.94
1.32
49.21
0.39
4.70
0.24
1136
23.01
Terpene
n.d.
-
n.d.
-
n.d.
-
1.55
0.36
1.39
0.11
n.d.
-
1.43
0.05
n.d.
-
1083
23.35
4,8-Epoxy-p-m
enth-1-ene
1.30
0.08
2.08
0.23
n.d.
-
2.22
0.03
6.44
0.16
3.08
0.03
5.20
0.60
1.32
0.01
1164
23.48
Linalooloxide
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.11
0.03
17.95
0.94
1.51
0.01
n.d.
-
1221
23.68
↵
-Y
langene
n.d.
-
1.09
0.23
n.d.
-
n.d.
-
0.52
0.00
2.19
0.09
n.d.
-
1.18
0.07
1082
25.29
 
-Linalool
5.52
0.81
2.22
0.32
10.55
1.27
0.82
0.01
5.19
0.01
1471.75
15.90
5.36
0.37
n.d.
-
1494
25.75
 -C
aryophyllene
n.d.
-
5.87
1.68
2.02
0.24
1.03
0.06
1.81
0.05
30.72
1.10
1.32
0.04
4.40
0.17
1430
26.03
↵
-Bergam
otene
2.42
0.21
11.89
3.95
1.75
0.08
2.21
0.19
2.31
0.02
40.96
0.21
1.01
0.08
9.44
0.07
1456
26.12
↵
-G
uaiene
2.46
0.05
n.d.
-
7.19
0.57
n.d.
-
n.d.
-
5.20
0.18
n.d.
-
n.d.
-
1494
26.23
Trans-caryophyllene
17.34
1.81
159.92
49.08
90.68
7.15
40.67
3.44
48.77
1.93
425.63
7.84
32.06
4.48
110.41
1.33
M
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C
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)
A
verage
c
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SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
Terpenes
1209
26.40
4-Terpineol
2.32
0.23
3.34
0.62
0.55
0.06
n.d.
-
2.80
0.24
15.34
1.66
1.71
0.18
n.d.
-
1440
26.59
Sesquiterpene
n.d.
-
3.03
0.70
1.37
0.18
n.d.
-
1.64
0.07
17.73
0.11
n.d.
-
1.13
0.10
1386
27.21
Sesquiterpene
n.d.
-
6.09
2.17
n.d.
-
n.d.
-
0.58
0.05
12.62
0.59
n.d.
-
7.01
0.26
1131
27.47
Trans-pinocarveol
n.d.
-
9.69
1.69
n.d.
-
n.d.
-
3.04
0.07
10.99
0.49
2.30
0.08
5.12
0.08
1482
27.73
↵
-H
um
ulene
6.28
0.44
45.95
15.88
21.61
1.49
10.13
1.54
9.62
0.69
117.14
3.27
5.94
0.88
32.25
1.15
1189
28.13
1,8-M
enthadien-4-ol
6.23
1.02
21.18
4.16
n.d.
-
2.19
0.43
19.68
0.44
44.91
2.39
12.61
0.58
6.86
0.41
1209
28.32
↵
-Terpineol
2.79
0.43
3.31
0.85
1.13
0.02
n.d.
-
2.90
0.24
14.35
1.10
1.83
0.04
0.63
0.07
1189
28.40
Borneol
0.52
0.04
2.78
0.74
n.d.
-
n.d.
-
0.64
0.04
1.59
2.25
n.d.
-
n.d.
-
1490
28.65
 -G
uaiene
1.56
0.01
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1519
28.72
 
-Selinene
0.85
0.01
11.64
4.28
1.65
0.02
0.96
0.19
1.46
0.13
41.02
1.77
0.85
0.17
8.15
0.36
1522
28.82
↵
-Selinene
1.04
0.01
7.51
2.69
1.06
0.14
n.d.
-
1.04
0.06
26.41
1.64
n.d.
-
4.51
0.20
1474
28.98
Sesquiterpene
n.d.
-
1.88
0.58
n.d.
-
n.d.
-
n.d.
-
53.97
6.99
n.d.
-
0.92
0.02
1190
29.03
C
arvone
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1507
29.86
Selina-3,7(11)-diene
n.d.
-
6.79
2.41
n.d.
-
0.96
0.31
1.85
0.06
25.33
2.61
n.d.
-
3.78
0.21
1191
30.13
M
yrtenol
n.d.
-
1.49
0.26
n.d.
-
n.d.
-
0.94
0.04
3.18
0.40
n.d.
-
0.80
0.03
1284
31.17
C
um
inol
4.00
0.64
7.44
1.98
n.d.
-
0.54
0.07
7.87
0.61
30.26
3.84
7.02
0.08
1.46
0.10
1322
33.41
H
um
ulene
oxide
n.d.
-
2.22
0.92
0.72
0.13
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.36
0.14
1419
34.11
Sesquiterpene
n.d.
-
n.d.
-
1.54
0.03
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1392
34.86
Eugenol
n.d.
-
n.d.
-
n.d.
-
n.d.
-
0.82
0.00
1.12
0.05
1.17
0.02
n.d.
-
Total
314.90
457.03
174.05
1000.37
1339.56
21860.3
1367.63
644.70
M
iscellaneous
906
11.03
3,3,6-Trim
ethyl-1,5-heptadiene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
11.87
0.33
n.d.
-
n.d.
-
907
12.72
1,3-D
im
ethyl-benzene
n.d.
-
0.96
0.08
n.d.
-
2.17
0.38
n.d.
-
1.41
0.02
n.d.
-
n.d.
-
1040
16.87
2-Pentyl-furan
n.d.
-
1.82
0.20
n.d.
-
n.d.
-
0.24
0.01
3.94
0.10
n.d.
-
1.99
0.07
1020
18.31
1,2,4,-Trim
ethyl-benzene
n.d.
-
n.d.
-
1.35
0.38
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
894
19.54
2,5-D
im
ethyl-pyrazine
1.03
0.05
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.23
0.04
n.d.
-
n.d.
-
891
19.74
2,6-D
im
ethyl-pyrazine
0.82
0.03
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1176
20.72
1,4-Bis
(1-m
ethylethyl)-benzene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.81
0.01
n.d.
-
n.d.
-
985
21.89
2,6-D
im
ethyl-2,6-octadiene
n.d.
-
n.d.
-
3.25
0.14
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1081
22.10
D
iethylcarbitol
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1039
22.36
1,3,5-Trim
ethylenecycloheptane
n.d.
-
1.07
0.26
n.d.
-
0.80
0.12
1.52
0.00
2.62
0.06
1.70
0.02
n.d.
-
986
28.45
5-Ethyldihydro-2(3H
)-furanone
n.d.
-
1.92
0.14
n.d.
-
n.d.
-
3.89
0.41
27.39
2.75
6.63
0.41
0.96
0.15
1190
30.85
1-M
ethoxy-4(1-propenyl)-benzene
n.d.
-
n.d.
-
n.d.
-
3.22
0.07
n.d.
-
n.d.
-
n.d.
-
n.d.
-
Total
1.85
7.19
4.60
6.19
8.38
54.23
10.93
2.95
M
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H
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H
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H
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O
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a
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C
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SD
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)
A
verage
c
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SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage c
µg/g
SD
(±
)
A
lcohols
831
20.63
1-H
exanol
6.19
0.32
2.66
0.08
2.00
0.14
4.37
0.20
0.67
0.02
3.52
0.23
9.67
0.16
868
21.43
3-H
exen-1-ol
n.d.
-
1.81
0.03
n.d.
-
n.d.
-
0.65
0.01
0.86
0.06
n.d.
-
849
22.02
2-H
exen-1-ol
n.d.
-
1.15
0.05
n.d.
-
0.62
0.07
0.63
0.00
n.d.
-
n.d.
-
969
23.07
1-O
cten-3-ol
1.08
0.03
0.79
0.01
1.26
0.13
1.23
0.07
n.d.
-
1.35
0.00
n.d.
-
960
23.17
1-H
eptanol
n.d.
-
n.d.
-
n.d.
-
0.72
0.04
n.d.
-
n.d.
-
n.d.
-
1059
25.48
1-O
ctanol
n.d.
-
0.58
0.11
n.d.
-
n.d.
-
n.d.
-
2.30
0.25
n.d.
-
1068
27.98
3,3,6-Trim
ethyl-1,5-heptadien-4-ol
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.56
0.10
n.d.
-
1036
31.59
↵
-Toluenol
n.d.
-
3.03
0.35
n.d.
-
1.39
0.15
n.d.
-
2.08
0.61
n.d.
-
1136
32.06
Benzeneethanol
0.62
0.03
3.07
0.62
n.d.
-
1.25
0.01
0.87
0.13
2.72
0.98
n.d.
-
Total
7.89
13.09
3.26
9.57
2.82
14.38
9.67
A
ldehydes
508
2.31
Propanal
n.d.
-
1.04
0.00
n.d.
-
n.d.
-
0.97
0.02
0.62
0.10
n.d.
-
574
3.23
2-M
ethyl-2-propenal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
643
3.74
2-M
ethyl-butanal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
643
3.83
3-M
ethyl-butanal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
785
10.12
H
exanal
6.35
0.40
2.53
0.01
10.51
0.36
7.04
0.29
3.18
0.36
2.60
0.18
1.80
0.12
905
15.05
H
eptanal
n.d.
-
0.63
0.03
0.46
0.02
n.d.
-
n.d.
-
n.d.
-
n.d.
-
814
16.24
2-H
exenal
1.23
0.06
1.41
0.03
1.02
0.02
0.53
0.75
11.50
0.40
0.82
0.04
n.d.
-
1005
18.74
O
ctanal
n.d.
-
1.92
0.07
n.d.
-
1.93
0.32
n.d.
-
n.d.
-
n.d.
-
913
19.72
2-H
eptenal
1.17
0.05
1.72
0.09
5.21
0.57
8.29
0.77
1.54
0.00
5.44
0.12
1.11
0.02
1104
21.67
N
onanal
n.d.
-
1.20
0.14
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1013
22.53
2-O
ctenal
1.49
0.02
n.d.
-
n.d.
-
0.95
0.00
n.d.
-
n.d.
-
n.d.
-
921
24.01
2,4-H
eptadienal
8.05
0.11
n.d.
-
2.31
0.19
1.37
0.20
n.d.
-
1.24
0.02
n.d.
-
982
24.77
Benzaldehyde
1.45
0.18
n.d.
-
1.90
1.67
1.55
0.31
0.43
0.10
8.46
3.09
n.d.
-
1174
28.04
3,7-D
im
ethyl-2,6-octadienal
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.30
0.07
n.d.
-
Total
19.73
10.43
21.41
21.66
17.61
20.48
2.92
M
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O
il
R
I
a
R
.T
b
C
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A
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c
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SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage c
µg/g
SD
(±
)
487
2.63
A
cetic
acid-m
ethylester
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
586
3.33
A
cetic
acid-ethylester
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
686
5.35
A
cetic
acid-propylester
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
721
6.77
A
cetic
acid-2-m
ethyl-propylester
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
785
9.76
A
cetic
acid-buthylester
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
820
12.27
1-Butanol-3-m
ethylacetate
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
992
19.62
3-H
exen-1-ol-acetate
n.d.
-
0.66
0.01
n.d.
-
n.d.
-
0.82
0.08
n.d.
-
n.d.
-
1183
22.24
Butanoic
acid-hexylester
n.d.
-
0.53
0.04
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
Total
n.d.
1.19
n.d.
n.d.
0.82
n.d.
n.d.
K
etones
455
2.50
2-Propanone
0.63
0.04
2.20
0.24
0.54
0.05
2.11
0.02
0.78
0.15
2.41
0.45
n.d.
-
1161
13.19
1-(1,3-dim
ethyl-3-cyclohexen-1-yl)-Ethanone
n.d.
-
n.d.
-
n.d.
-
2.75
0.05
n.d.
-
0.89
0.05
n.d.
-
853
14.89
2-H
eptanone
n.d.
-
2.70
0.03
1.05
0.04
1.32
0.02
n.d.
-
1.45
0.36
n.d.
-
952
18.57
2-O
ctanone
n.d.
-
n.d.
-
5.08
0.42
0.55
0.03
n.d.
-
n.d.
-
n.d.
-
960
19.99
6-O
cten-2-one
n.d.
-
n.d.
-
0.80
0.04
n.d.
-
n.d.
-
n.d.
-
n.d.
-
987
20.17
6-M
ethyl-5
hepten-2
one
0.73
0.10
1.65
0.06
0.53
0.03
6.00
0.58
0.76
0.04
6.50
0.28
n.d.
-
960
21.96
3-O
cten-2-one
n.d.
-
n.d.
-
0.57
0.05
n.d.
-
n.d.
-
n.d.
-
n.d.
-
962
22.51
K
etone
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
0.71
0.01
n.d.
-
968
24.67
3,5-O
ctadien-2-one
0.59
0.07
n.d.
-
1.44
0.17
1.44
0.13
n.d.
-
1.39
0.20
n.d.
-
Total
1.94
6.55
10.01
14.16
1.54
13.35
n.d.
Terpenes
939
6.67
↵
-Pinene
1.35
0.06
120.21
0.54
4.27
0.25
147.07
1.23
n.d.
-
94.47
3.96
2.27
0.07
932
7.03
↵
-Thujene
n.d.
-
2.86
0.13
n.d.
-
9.40
0.18
n.d.
-
2.16
0.11
n.d.
-
961
8.67
C
am
phene
n.d.
-
1.69
0.15
n.d.
-
3.04
0.02
n.d.
-
7.45
0.26
n.d.
-
989
10.75
 
-Pinene
0.70
0.00
37.67
1.33
1.30
0.14
33.28
0.36
n.d.
-
21.91
0.34
0.87
0.01
985
11.66
Sabinene
n.d.
-
1.64
0.13
n.d.
-
0.71
0.05
n.d.
-
n.d.
-
n.d.
-
879
11.74
2,4(10)-Thujadien
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1017
12.99
 -3-C
arene
n.d.
-
48.70
4.87
n.d.
-
3.82
0.10
n.d.
-
6.63
0.99
n.d.
-
1015
13.81
↵
-Phellandrene
n.d.
-
7.37
0.11
n.d.
-
2.59
0.40
n.d.
-
3.70
0.60
n.d.
-
991
14.24
 
-M
yrcene
13.88
2.66
429.64
5.70
10.12
0.33
344.78
5.22
n.d.
-
74.69
5.07
10.65
0.30
1026
14.44
↵
-Terpinene
n.d.
-
4.29
0.26
n.d.
-
2.35
0.19
n.d.
-
2.95
0.49
n.d.
-
1038
15.31
Lim
onene
2.38
0.50
20.56
0.29
2.40
0.15
50.09
1.95
n.d.
-
23.56
1.63
5.53
0.46
1045
15.49
Eucalyptol
n.d.
-
3.13
0.02
0.41
0.06
15.41
0.72
0.56
0.09
17.91
0.72
n.d.
-
946
15.61
 
-Phellandrene
n.d.
-
20.96
0.14
n.d.
-
7.16
0.27
n.d.
-
13.75
0.51
n.d.
-
976
17.05
C
is-ocim
ene
n.d.
-
19.76
0.13
n.d.
-
5.45
0.45
n.d.
-
7.22
0.43
n.d.
-
1066
17.15
 -Terpinene
n.d.
-
4.77
0.03
n.d.
-
7.17
0.43
n.d.
-
4.59
0.24
n.d.
-
M
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verage
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A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage c
µg/g
SD
(±
)
Terpenes
1000
17.24
Terpene
0.87
0.01
1.88
0.14
n.d.
-
n.d.
-
n.d.
-
1.30
0.17
n.d.
-
1029
17.60
 
-O
cim
ene
4.44
0.07
217.33
2.36
2.42
0.28
40.93
2.46
0.88
0.01
24.18
1.39
2.91
0.27
1034
18.01
p-C
ym
ene
n.d.
-
10.17
0.39
0.66
0.05
43.02
2.52
0.66
0.27
13.51
0.89
n.d.
-
1094
18.43
↵
-Terpinolene
3.55
0.19
249.23
0.57
0.76
0.07
52.02
3.15
n.d.
-
16.01
1.06
1.00
0.07
1177
22.74
Para-cym
enyl
1.81
0.11
47.64
0.55
0.56
0.20
7.84
0.51
1.07
0.02
7.16
0.93
n.d.
-
1136
23.01
Terpene
n.d.
-
1.67
0.11
n.d.
-
0.53
0.06
n.d.
-
n.d.
-
n.d.
-
1083
23.35
4,8-Epoxy-p-m
enth-1-ene
n.d.
-
5.65
0.01
n.d.
-
2.49
0.35
n.d.
-
n.d.
-
n.d.
-
1164
23.48
Linalooloxide
0.70
0.01
1.37
0.40
n.d.
-
2.96
0.25
n.d.
-
n.d.
-
n.d.
-
1221
23.68
↵
-Y
langene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1082
25.29
 
-Linalool
n.d.
-
6.35
0.07
n.d.
-
3.98
0.45
n.d.
-
4.90
0.14
n.d.
-
1494
25.75
 -C
aryophyllene
8.60
1.21
1.63
0.09
0.57
0.00
5.30
0.59
1.23
0.05
8.86
1.07
n.d.
-
1430
26.03
↵
-Bergam
otene
6.78
1.09
1.06
0.24
0.53
0.03
11.82
1.57
2.94
0.11
19.89
3.59
n.d.
-
1456
26.12
↵
-G
uaiene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1.08
0.19
n.d.
-
1494
26.23
Trans-caryophyllene
78.99
10.43
39.18
2.69
4.72
0.14
92.75
9.99
15.78
0.51
228.18
33.12
1.62
0.28
1209
26.40
4-Terpineol
n.d.
-
2.07
0.13
n.d.
-
3.74
0.68
n.d.
-
2.46
0.32
n.d.
-
1440
26.59
Sesquiterpene
n.d.
-
n.d.
-
n.d.
-
2.50
0.02
n.d.
-
2.80
1.76
n.d.
-
1386
27.21
Sesquiterpene
1.73
0.24
n.d.
-
n.d.
-
6.03
0.75
1.56
0.03
7.09
1.10
n.d.
-
1131
27.47
Trans-pinocarveol
n.d.
-
2.74
0.03
n.d.
-
8.40
0.80
0.85
0.10
2.41
0.17
n.d.
-
1482
27.73
↵
-H
um
ulene
31.19
5.31
7.35
0.58
1.28
0.04
27.08
3.69
5.27
0.05
68.14
12.59
n.d.
-
1189
28.13
1,8-M
enthadien-4-ol
2.13
0.13
15.23
1.04
1.44
0.81
12.22
1.05
2.44
0.08
19.06
0.12
n.d.
-
1209
28.32
↵
-Terpineol
n.d.
-
2.13
0.19
n.d.
-
3.26
0.03
0.76
0.12
3.59
1.20
n.d.
-
1189
28.40
Borneol
n.d.
-
n.d.
-
n.d.
-
1.13
0.09
n.d.
-
n.d.
-
n.d.
-
1490
28.65
 -G
uaiene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1519
28.72
 
-Selinene
6.81
1.46
0.90
0.15
n.d.
-
8.70
1.17
3.03
0.03
13.72
2.84
n.d.
-
1522
28.82
↵
-Selinene
3.53
0.59
1.05
0.12
n.d.
-
5.44
0.74
1.81
0.05
9.48
1.82
n.d.
-
1474
28.98
Sesquiterpene
1.60
0.24
n.d.
-
n.d.
-
1.01
0.15
0.58
0.04
2.13
0.41
n.d.
-
1190
29.03
C
arvone
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
0.79
0.14
1507
29.86
Selina-3,7(11)-diene
5.95
1.25
1.88
0.33
n.d.
-
n.d.
-
1.86
0.03
6.99
1.18
n.d.
-
1191
30.13
M
yrtenol
n.d.
-
n.d.
-
n.d.
-
1.23
0.16
n.d.
-
n.d.
-
n.d.
-
1284
31.17
C
um
inol
1.51
0.26
8.56
1.41
n.d.
-
3.13
0.07
0.97
0.11
6.46
1.79
n.d.
-
1322
33.41
H
um
ulene
oxide
1.71
0.47
n.d.
-
n.d.
-
1.54
0.32
0.92
0.05
2.44
0.37
n.d.
-
1419
34.11
Sesquiterpene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1392
34.86
Eugenol
0.76
0.15
1.18
0.14
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
Total
180.97
1349.52
31.43
981.37
43.15
752.82
25.64
M
olecules2018,23,1230
14
of22
Table
2.C
ont.
O
ilSam
ples
9
10
11
12
13
14
15
M
atrix
H
em
p
Seed
O
il
O
live
O
il
H
em
p
Seed
O
il
H
em
p
Seed
O
il
O
live
O
il
H
em
p
Seed
O
il
H
em
p
Seed
O
il
R
I
a
R
.T
b
C
om
pound
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
verage
c
µg/g
SD
(±
)
A
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A
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c
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A
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c
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A
verage c
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SD
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M
iscellaneous
906
11.03
3,3,6-Trim
ethyl-1,5-heptadiene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
907
12.72
1,3-D
im
ethyl-benzene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
1040
16.87
2-Pentyl-furan
3.01
0.27
n.d.
-
0.56
0.04
n.d.
-
n.d.
-
1.26
0.12
n.d.
-
1020
18.31
1,2,4,-Trim
ethyl-benzene
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
894
19.54
2,5-D
im
ethyl-pyrazine
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
n.d.
-
891
19.74
2,6-D
im
ethyl-pyrazine
n.d.
-
n.d.
-
n.d.
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Figure 2. Terpenes classes quantified in CBD based oils preparations (expressed as µg/g IS equivalents)
(a) Mono/di/tri Terpenes (b) sesquiterpenes and oxygenated terpenes.
 -Myrcene and limonene accompanied by  -ocimene and trans-caryophyllene were found in
all samples, but in a much reduced amounts compared to sample 6, and their concentration differed
greatly from sample to sample. ↵-Pinene and  -pinene were identified in the majority of samples,
excluding samples Oil_3 and Oil_13. This remains unclear considering that the two pinenes are quite
balanced within the different Cannabis varieties representing around the 10% of the terpenes group
and not exceeding 15–20% [20]. The occurrence of ↵-terpinolene in all samples (except Oil_2 and
Oil_13), might be important as this compound was suggested as a genetic marker for distinguishing
two important gene pools for breeding low-THC varieties [35,36]. Sample Oil_14 was particularly rich
in trans-caryophyllene followed by ↵-humulene. The dominance of those two sesquiterpenes over the
other terpenes detected in this preparation may indicate the geographic provenience of the starting
Cannabis sativamaterial, and as a matter of fact, the producer specified the mountain region where the
plant was cultivated.
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It is also important to notice that sample Oil_15 was almost completely deprived of
a terpene fraction aside from the traces of the main three mentioned above. This might indicate
an inefficient/inadequate processing of the starting materials or even artificial addition of CBD to the
oil matrix, as some essential cannabinoids were also missing (Table 1). In addition, extremely low
terpene content was established for samples 11 and 13, while the remaining samples had total terpene
contents in the range between 174 and 1367 µg/g, with pronounced variation in composition from
sample to sample. Nevertheless, qualitative and quantitative differences observed in the chemical
profiles of terpene fractions are conditioned by many factors such as: hemp variety, cultivation and
environmental conditions harvest time and post-harvest conditions, storage and drying of raw plants,
extraction procedure applied, matrix used and finally storage of the oil formulation.
Besides hydrocarbon terpenes, oxygenated terpenoids such as linalool and ↵-terpineol,
were found in some preparations (Table 2, Figure 2) with a notably high concentration again in sample
Oil_6. Those compounds correspond to secondary photooxidation products of the initial terpenes.
In the presence of light and singlet oxygen, terpenes are also known to undergo photooxidation leading
to the formation of allylic hydroperoxides [35].
In addition to the terpene compound profiles that accounted for more than 90% of the detected
volatile constituents of the oils, it was possible to note the presence of other organic compounds
commonly found in natural extracts such as esters, alcohols, aldehydes and ketones (Table 2).
Only a few low chain esters could actually be identified, with ethyl acetate dominating in sample Oil_3.
Its presence is most likely to be due to the preparation method and could also be considered indicative
of potential adulteration.
On the another hand, the detection of aldehydes and ketones suggests the initiation of lipid
peroxidation of polyunsaturated fatty acids (PUFA) in the oils used as a matrix, as demonstrated in
our previous work concerning the observed trends of these compounds during storage of macerated
Cannabis-derived oils [12]. It is well documented that peroxidation of PUFA leads to the formation
of a well-defined series of aldehydes and ketones such as nonenal, hexanal and pentanal, 2-heptenal,
especially during storage. The rate of formation of lipid oxidation products depends strictly on
several factors, among which the most important are the preparation method temperature, fatty acid
composition of the oil in which Cannabis extract was dissolved and the storage conditions (storage
temperature) as recently demonstrated in a study [12]. These parameters are crucial to define
the ultimate characteristics of the final products as evidenced also by the color of the samples
(Figure 3). Other volatile decomposition compounds frequently encountered include 2-hexenal,
2-octenal, 2,4-nonadienal, 4,5-dihydroxydecenal [37], some of which also appeared to be present in
some of our samples.
For the CBD oils analyzed in this study, tree different oil typologies were used: medium chain
triglycerides (MCT oil, one sample), olive oil (six samples) and hemp seed oil (eight samples). It is worth
emphasizing that sample Oil_4 was almost completely deprived of lipid oxidation products (Table 2,
Figure 4). This preparation was the only one prepared in MCT oil, which means that this kind of matrix
is less susceptible to oxidative degradation than the olive or hemp seed oils declared as matrices for
other preparations enrolled herein
As far as olive oil is concerned, is often used by producers as it has a strong nutritional potential,
being rich in the polyunsaturated fatty acids. Moreover, FU oil (pharmaceutical grade olive oil) is used
for the preparation of CBD galenic formulations [9,12,29] as it was performed for Bedrolite oil extract.
Regarding the hemp seed oil used as a carrier for dissolving the CBD extract (hence the term
“CBD hemp oil”) some clarifications regarding this kind of preparation are indispensable because
misconceptions that may confuse the final users of this preparations still exist. “CBD oil” expression is
typically limited to extracts in oil of flowering buds and not stalks, fibers, or seeds of eachCannabis sativa
L. variety. Hemp seeds do not contain any cannabinoids, but their contact with the resin secreted by the
epidermal glands located on flowers, and leaves and/or a bad selection of the bracts of the perigonium
can cause the appearance of some cannabinoids in hemp oil [34,38]. Therefore, any cannabinoids
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detected actually represent hemp seed oil contaminants. Their concentration is influenced by the
hemp variety and by the seed cleaning process. Although the cannabinoid concentration in hemp seed
oils is usually extremely low, it must be determined before oil commercialization [39]. Nevertheless,
the seeds of industrial hemp plants have important uses in human nutrition [40,41] and this is reason
why its oil is used as an adequate, naturally resembling matrix for CBD-enriched products. Hemp seed
oils represent good sources of protein, and are rich in omega-3 and omega-6 fatty acids with an ideal
n3/n6 PUFA nutrition ratio according to WHO guidelines [42,43]. It should be considered that hemp
oil is rich in unsaturated fatty acids which are the components susceptible to oxidation phenomena
during storage. Although hemp seed oil was shown to be more predisposed to peroxidation than
olive oil [44], this study did not identify any significant differences between these two matrixes as far
as on-going peroxidation was concerned. Nevertheless, the critical point is to assess stability during
the storage period, that is not reported or available for any of the CBD preparations analysed here.
This represents a fundamental issue since the formation of lipid oxidation products is related with the
decreasing concentration of cannabinoids and terpenes, as well [12]. Therefore, the investigation of
trends of compounds characterizing the formulations is essential to define the management conditions.
Moreover, an adequate storage temperature would be useful to define the correct expiry date of the
products as they are commercialized in EU as dietary supplements.
 
Figure 3. Different colors observed in CBD-based oil products.
 
Figure 4. Lipid oxidation products quantified in CBD based oils preparations (expressed as µg/g SI
equivalents).
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3. Materials and Methods
3.1. Materials
Fourteen samples of commercially available CBDs oil were purchased on the Internet between
December 2017 and January 2018. The purchase was based on the main product brands available on
the European market. Table 3 summarizes the main characteristics of the samples. Samples were kept
at room temperature (as indicated by the manufacturers) before analyses and sample codes (Oils 2–15)
were assigned to them in accordance with the order of acquisition. Bedrolite® oil olive extract (assigned
as Oil_1) was obtained from a Bedrolite Bedrocan International, Postbus, CA, Veendam, Netherlands®
medical Cannabis chemotype. Exhaustive analytical procedures were described in details in our recently
published article [12].
Table 3. Declared CBD content, oil matrix used and origin of the analysed CBD oil samples.
Samples CBD DeclaredContent (%, w/w) Matrix Origin
Extraction Method
(When Indicated)
Oil_1 / Olive oil Italy Calvi et al., 2018
Oil_2 4 Hemp seed oil Switzerland ND *
Oil_3 1 Olive oil Switzerland ND
Oil_4 5 Caprylic/Capric Triglyceride (MCT) Italy ND
Oil_5 4 Olive oil Switzerland CO2 supercritical
Oil_6 3 Hemp oil The Netherlands CO2 supercritical
Oil_7 4 Olive oil Spain ND
Oil_8 3 Hemp seed oil The Netherlands ND
Oil_9 3 Hemp seed oil The Netherlands ND
Oil_10 4 Olive oil The Netherlands ND
Oil_11 / Hemp seed oil Switzerland ND
Oil_12 2 Hemp seed oil Switzerland CO2 supercritical
Oil_13 4 Olive oil France ND
Oil_14 5 Hemp seed oil Slovenia CO2 supercritical
Oil_15 3 Hemp seed oil UK ND
* ND—not declared.
3.2. Chemical and Reagents
All HPLC or analytical grade chemicals were from Sigma (Sigma–Aldrich, St. Louis, MO, USA).
Formic acid 98–100% was from Fluka (Sigma–Aldrich, St. Louis, MO, USA). Ultrapure water was
obtained through a Milli-Q system (Millipore, Merck KGaA, Darmstadt, Germany). For head-space
(HS) analysis, the SPME coating fiber (DVB/CAR/PDMS, 50/30 µm) was from Supelco (Bellefonte,
PA, USA). Acetonitrile, 2-propanol, formic acid LC-MS grade were purchased from Carlo Erba
(Milan, Italy). CBD, THC, CBN, CBG, CBNA, THCA, CBGA were purchased from Sigma Aldrich
(Round Rock, TX, USA).
3.3. Terpenes GC-MS Analysis
One hundredmg of each oil sample were weighed and put into 20mL glass vials alongwith 100 µL
of the inyernal standard (IS, 4-nonylphenol, 2000 µg/mL in 2-propanol). Each vial was fitted with
a cap equipped with a silicon/PTFE septum (Supelco). A temperature of 37  C was selected as both
as the extraction and equilibration temperature according to previous published research, in order to
prevent possible matrix alterations ensuring the most efficient adsorption of volatile compounds onto
the SPME fibre [15,16]. To keep the temperature constant during analysis, the vials were maintained in
a cooling block (CTC Analytics, Zwingen, Switzerland). At the end of the sample equilibration time
(30 min), a conditioned (60 min at 280  C) SPME fiber was exposed to the headspace of the sample for
120 min using a CombiPAL system injector autosampler (CTC Analytics). All analytical parameters
were already validated in our previous research [12].
Analyses were performed with a Trace GC Ultra coupled to a Trace DSQII quadrupole mass
spectrometer (MS) (Thermo-Fisher Scientific, Waltham, MA, USA) equipped with an Rtx-Wax column
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(30 m ⇥ 0.25 mm i.d. ⇥ 0.25 µm film thickness) (Restek, Bellefonte, PA, USA). The oven temperature
program was: from 35  C, held for 8 min, to 60  C at 4  C/min, then from 60 to 160  C at 6  C/min
and finally from 160 to 200 at 20  C/min. Helium was the carrier gas, at a flow rate of 1 mL/min.
Carry over and peaks originating from the fibres were regularly assessed by running blank samples.
After each analysis fibres were immediately thermally desorbed in the GC injector for 5 min at 250  C
to prevent contamination. The MS was operated in electron impact (EI) ionisation mode at 70 eV.
An alkanes mixture (C8-C22, Sigma R 8769) was run under the same chromatographic conditions as the
samples to calculate the Kovats Retention Indices (RI) of the detected compounds. The mass spectra
were obtained by using a mass selective detector, a multiplier voltage of 1456 V, and by collecting the
data at rate of 1 scan/s over the m/z range of 35–350. Compounds were identified by comparing the
retention times of the chromatographic peaks with those of authentic compounds analyzed under
the same conditions when available, by comparing the Kovats retention indices with the literature
data and through the National Institute of Standards and Technology (NIST) MS spectral database.
The quantitative evaluation was performed using the internal standard procedure and the results were
finally expressed as µg/g or mg/g IS equivalents of each volatile compounds. All analyses were done
in triplicate.
3.4. Cannabinoids LC-Q-Exactive-Orbitrap-MS Analysis
The cannabinoids profile and content were evaluated by the procedure recently published by
us [12]. Briefly, the oil samples for HPLC-Q-Exactive-Orbitrap-MS analysis were prepared by dissolving
100 mg of each oil in 10 mL of isopropanol. After adding the 1 µg/mL of IS, 10 µL of each sample
were diluted in 890 µL of initial mobile phase from which 2 µL was injected. Chromatography was
accomplished on an HPLC system (Thermo Fisher Scientific, San Jose, CA, USA) that was made up of
a Surveyor MS quaternary pump with a degasser, a Surveyor AS autosampler with a column oven
and a Rheodyne valve with a 20 µL loop. Analytical separation was carried out using a reverse-phase
HPLC column 150 ⇥ 2 mm i.d., 4 µm, Synergi Hydro RP, with a 4 ⇥ 3 mm i.d. C18 guard column
(Phenomenex, Torrance, CA, USA). Themobile phase used in the chromatographic separation consisted
of a binary mixture of solvents A (0.1% aqueous formic acid) and B (acetonitrile). The gradient was
initiated with 60% eluent A with a linear decrease up to 95% in 10 min. This condition was maintained
for 4 min. The mobile phase was returned to initial conditions at 14 min, followed by a 6-min
re-equilibration period (total run time: 20 min). The flow rate was 0.3 mL/min. The column and
sample temperatures were 30  C and 5  C, respectively. The mass spectrometer Thermo Q-Exactive
Plus (Thermo Scientific) was equipped with a heated electrospray ionisation (HESI) source. Capillary
temperature and vaporiser temperature were set at 330 and 280  C, respectively, while the electrospray
voltage was adjusted at 3.50 kV (operating in both positive and negative mode). Sheath and auxiliary
gas were 35 and 15 arbitrary units, with S lens RF level of 60. The mass spectrometer was controlled by
the Xcalibur 3.0 software (Thermo Fisher Scientific). The exact mass of the compounds was calculated
using Qualbrowser in Xcalibur 3.0 software. The FS-dd-MS2 (full scan data-dependent acquisition) in
both positive and negative mode was used for both screening and quantification purposes. Resolving
power of FS adjusted on 140,000 FWHM at m/z 200, with scan range of m/z 215–500. The automatic
gain control (AGC) was set at 3 ⇥ 106, with an injection time of 200 ms. A targeted MS/MS (dd-MS2)
analysis operated in both positive and negative mode at 35,000 FWHM (m/z 200). The AGC target was
set to 2 ⇥ 105, with the maximum injection time of 100 ms. Fragmentation of precursors was optimised
as two-stepped normalised collision energy (NCE) (25 and 40 eV). Detection was based on calculated
exact mass of the protonated/deprotonated molecular ions, at least one corresponding fragment and
on retention time of target compounds [12]. Extracted ion chromatograms (EICs) were obtained with
an accuracy of 2 ppm m/z from total ion chromatogram (TIC) engaging the m/z corresponding to the
molecular ions [M + H]+ 315,23145 for CBD and THC, 311,20020 for CBN, 317.24716 for CBG and
311.2024 for CBN. In ESI- the molecular ions [M H]  considered were 357.2164 for CBDA and THCA,
while CBGA was detected by 359,22269.
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4. Conclusions
Taken together, the results presented in this study indicate the pronounced variability of
CBD concentrations in commercialized CBD oil preparations. The differences found in the overall
cannabinoids profiles accompanied with discrepancies revealed for the terpenes fingerprint justify the
necessity to provide firmer regulation and control. Precise information regarding CBD oil composition
is crucial for consumers, as individual doses throughout the administration period have to be adapted
according to CBD bioavailability. This is of fundamental importance regarding consumer safety,
as CBD oil preparations are also used in therapeutical purposes, regardless of the fact that they are
registered as dietary supplements.
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